Why Vertex Stock Sank 42% In 2016

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a biopharmaceutical company with a leading role in cystic fibrosis treatment, sank 42.5% last year, according to data from S&P Global Market Intelligence. Although the company has narrowed its losses, investors didn't appreciate another year in the red. An apparent slowdown for its only commercial-stage drugs didn't sit well with the market.

Back to news